Alexander, S. & Friedl, P. Cancer invasion and resistance: interconnected processes of disease progression and therapy failure.
Six additional patients received surgical salvage for radiation therapy failure.
The appearance of these mutations may result in therapy failure.
Minority HIV-1 populations with resistance mutations might result in therapy failure.
If there was one therapy failure, 21 additional patients were tested, and if there were two or more failures, then the resistance level was 10percentt or more.
Inadequate infliximab (IFX) drug exposure remains a clinical challenge and leads to high loss of response rates and therapy failure in inflammatory bowel disease (IBD).
Patients who underwent surgical salvage after radiation therapy failure had a 1-year survival rate of 0%.
Resistance-associated variants (RAVs) can limit the efficacy of DAA therapy and are associated with increased risk for therapy failure.
This highlights a need for research into the mechanisms behind its etiology and causes of therapy failure.
Incomplete inhibition of AURKA was a common source of therapy failure, and combinations of PI3K, AKT or mTOR inhibitors with the AURKA inhibitor MLN8237 were highly synergistic and durably suppressed mTOR signaling, resulting in apoptosis and tumor regression in vivo.
Mechanisms underlying cancer therapy failure and treatment resistance are summarized.
